Groopman J E
Department of Medicine, New England Deaconess Hospital, Boston, Massachusetts 02215.
Am J Med. 1991 Apr 10;90(4A):18S-21S. doi: 10.1016/0002-9343(91)90406-n.
A number of studies have illustrated the effectiveness of hematopoietic growth factors in managing treatment-related cytopenias in patients with human immunodeficiency virus (HIV) infection. One of these factors, granulocyte-macrophage colony-stimulating factor, has been shown to restore absolute neutrophil counts in patients with acquired immunodeficiency syndrome (AIDS) and Kaposi's sarcoma receiving a combination of zidovudine (AZT) and interferon alfa. A combination of granulocyte colony-stimulating factor and erythropoietin has also been demonstrated to alleviate both neutropenia and anemia in patients with advanced AIDS or AIDS-related complex receiving zidovudine. Hematopoietic growth factors, in combination with each other and with antiretroviral agents, thus have an important supportive role to play in the treatment of patients with HIV disease.
多项研究已阐明造血生长因子在治疗人类免疫缺陷病毒（HIV）感染患者的治疗相关血细胞减少症方面的有效性。其中一种因子，即粒细胞-巨噬细胞集落刺激因子，已被证明可使接受齐多夫定（AZT）和干扰素α联合治疗的获得性免疫缺陷综合征（AIDS）和卡波西肉瘤患者的绝对中性粒细胞计数恢复正常。粒细胞集落刺激因子和促红细胞生成素的联合使用也已被证明可缓解接受齐多夫定治疗的晚期AIDS或AIDS相关综合征患者的中性粒细胞减少和贫血。因此，造血生长因子相互联合以及与抗逆转录病毒药物联合，在HIV疾病患者的治疗中具有重要的支持作用。
